HEMATOLOGY

General Cancer

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

Umbralisib was granted a breakthrough therapy designation by the FDA for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.

Mohamad Mohty, MD, PhD, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.

Treatment for Relapsed Chronic Lymphocytic Leukemia